Medical/Pharmaceuticals
PROVISION Study Which Met Its Primary Endpoint Now Demonstrates Similar Clinical Outcomes for FFRangio and FFR
PROVISION Study, Prospective Randomized Trial Evaluating Clinical Outcomes of FFRangio Versus FFR Guidance, Demonstrates Similar MACE Rates at One Year PARIS, May 22, 2025 /PRNewswire/ -- Today at the annual EuroPCR conference taking place in Paris, France, Dr. Toru Tanigaki of Gifu Heart Center...
2025-05-22 15:57
2047
JEC Hosts 5th International Ophthalmology Summit, Launches Groundbreaking Digital Eye Health Platform
* Global eye experts reunite in Jakarta for JECIM 2025, after five-year hiatus
* JEC showcases 41 years of ophthalmology leadership and innovation
* Launch of Matapedia marks new chapter in eye health education JAKARTA,
Indonesia, May 22, 2025 /PRNewswire/ -- JEC Eye Hospitals and Clinics
2025-05-22 14:00
2242
MGI Tech Unveils Next-Generation Automation Portfolio at SLAS Europe 2025 in Germany
HAMBURG, Germany, May 21, 2025 /PRNewswire/ -- MGI Tech Co., Ltd. (MGI), a company dedicated to developing core tools and technologies that drive innovation in life sciences, is proud to unveil its latest innovation, PrepALL, a flexible liquid handling system, along with the latest version of t...
2025-05-22 10:38
2028
Fourth NDA for Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) Accepted by the Center for Drug Evaluation
CHENGDU, China, May 22, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that a new indication application (the "Application") for the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotec...
2025-05-22 10:09
2607
AnnJi Pharmaceutical Company Announces Positive Phase 1/2a Results for AJ201 in Spinal and Bulbar Muscular Atrophy (SBMA) Patients
TAIPEI, May 22, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd., a clinical-stage Taiwanese biotechnology company focused on addressing unmet medical needs in dermatology, neurology, and rare diseases, today announced positive results from its Phase 1/2a randomized, double-blind, placebo-con...
2025-05-22 09:21
2396
Lethal mutations in pregnancy loss
REYKJAVIK, Iceland, May 21, 2025 /PRNewswire/ -- In a study published in Nature today "Sequence diversity lost in early pregnancy," scientists from deCODE genetics, a subsidiary of Amgen, estimate that around one in 136 pregnancies are lost due to new mutations in the fetus. In other words, milli...
2025-05-21 23:00
2757
Neurophet Participates ASNR 2025: Showcasing Clinical Utility of 'Neurophet AQUA AD'
* Co-CEO Jake Junkil Been joins Industry Collaboration Session to present Neurophet's brain imaging analysis technologies, including Neurophet AQUA AD * Company accelerates partnerships with global pharmaceutical companies and neurology KOLs to drive collaboration in Alzheimer's disease clinic...
2025-05-21 21:00
2775
Kailo Medical Acquires REI AI to Transform the Future of Radiology Reporting
Strategic acquisition brings generative AI into structured workflows, reinforcing Kailo's mission to deliver long-term impact through trusted, collaborative innovation. MELBOURNE, May 21, 2025 /PRNewswire/ -- Kailo Medical, a global leader in structured reporting for medical imaging, today anno...
2025-05-21 20:38
2181
BioDlink Clinches Brazil GMP Audit to Strengthen Emerging Markets Growth
* International recognition of quality system with GMP-compliance in the key markets ofBrazil, Indonesia, Egypt, Colombia and Argentina * Passed its first-ever on-site PIC/S audit, reinforcing its strong commitment to stringent international regulatory standards * Demonstrated BioDlink's cap...
2025-05-21 20:30
2213
China's Aphranel MagiCCrystal CaHA Filler Debuts Globally, Ushering in a New Era of Regenerative Aesthetic Medicine
SHANGHAI, May 21, 2025 /PRNewswire/ -- On May 8, 2025, Shanghai Moyom Biotechnology Co., Ltd. unveiled its breakthrough regenerative aesthetic innovation, Aphranel MagiCCrystal CaHA Filler, during an international product debut at The Grand Halls inShanghai, a historic building on the Bund. ...
2025-05-21 20:00
2794
SK bioscience Wins Patent Lawsuit Against Pfizer Over Pneumococcal Vaccine
* No patent infringement found in exports of individual conjugate bulk substances and research-use finished products of PCV13 toRussia * Company plans to export PCV13 vaccine components * "We aim for the global PCV market with our 21-valent and next-generation pneumococcal vaccines currently...
2025-05-21 20:00
2628
WHO Foundation and Laerdal Global Health announce US $12.5 million to launch massive Acute Care scale up aiming to save over 50,000 lives per year
Over half of deaths in low-and middle-income countries could be addressed with effective emergency care. GENEVA, May 21, 2025 /PRNewswire/ -- A newly-announced philanthropic partnership between Laerdal Global Health and the WHO Foundation will fund WHO to scale up acute care training for health...
2025-05-21 13:38
2815
Elyon Family Clinic Launches STD Testing Packages Amid Rising Sexual Health Awareness
SINGAPORE, May 21, 2025 /PRNewswire/ -- Elyon Family Clinic & Surgery, an STD
clinic in Singapore
2025-05-21 10:00
1581
Accropeutics Announces Positive Data from Phase 2 Trial of AC-201, an oral, selective TYK2/JAK1 Inhibitor, for the treatment of Moderate-to-Severe Plaque Psoriasis
* Phase 2 primary endpoint of PASI-75 and key secondary endpoints met in all of the three dosing groups at Week 12 * AC-201 was generally well tolerated at all dose levels with no SAEs or AEs leading to discontinuation * Efficacy and safety findings from this Phase 2 trial support advancing ...
2025-05-21 08:50
1738
PeproMene Bio, Inc. and the Institute for Follicular Lymphoma Innovation (IFLI) Announce The First Follicular Lymphoma (FL) Patient Treated with BAFF-R Targeting CAR-T Cells (PMB-CT01) Achieves a Complete Response
* The first heavily pretreated r/r FL patient dosed at City of Hope with PMB-CT01 achieved a CR at one-month post treatment. * A Total of 7/7 r/r B-NHL patients including MCL, DLBCL and FL treated with PMB-CT01 have achieved a sustained CR (1 to 29+ months) with strictly grade 1 CRS and ICAN...
2025-05-20 22:22
1925
Registrational Phase III AMPLIFY trial in biochemical recurrence of prostate cancer commences
SYDNEY, May 20, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that it has commenced ...
2025-05-20 21:02
2240
Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)
- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical compa...
2025-05-20 20:00
2271
Rockwell Automation Launches EtherNet/IP In-cabinet Solution to Help Manufacturers Build Smarter, More Efficient Panels
New offering can cut wiring time by up to 80%, speeding production and
innovation
MILWAUKEE, Wis., May 20, 2025 /PRNewswire/ -- Rockwell Automation, Inc.
2025-05-20 19:00
2276
Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC
SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety a...
2025-05-20 18:18
3706
Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity
- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with obesity. - Asan adipose-targeted, muscle-preserving...
2025-05-20 18:00
2333
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 319 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 317 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 277 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 256 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 250 media titles]
2026-02-16 08:00Most Read
eufy Raises the Bar for Home Cleaning with Omni C28, Delivering One-Pass-Clean Performance with HydroJet™ Self-Clean Roller Mop
2026-02-14 10:00
8535
The 139th Canton Fair Promotion Conferences to Be Held in Germany and Morocco, Highlighting Targeted Industry Opportunities
2026-02-14 13:00
6734
U Power to Present at OTC Markets AI & Technology Investor Conference on February 19
2026-02-14 01:00
6601